Obstructive sleep apnoe and cardiovascular, heart failure and mortality outcomes with empagliflozin versus placebo in the EMPA-REG OUTCOME trial

被引：0
|
作者：
Yaggi, H. K. [1 ]
Eliasson, B. [2 ]
Kasai, T. [3 ]
Marx, N. [4 ]
Zinman, B. [5 ]
Inzucchi, S. E. [1 ]
Wanner, C. [6 ]
Zwiener, I [7 ]
Wojeck, B. [1 ]
Neeland, I [8 ]
Johansen, O. [9 ]
机构：
[1] Yale Univ, Yale Sch Med, New Haven, CT USA
[2] Sahlgrens Acad, Gothenburg, Sweden
[3] Juntendo Univ, Dept Cardiovasc Med, Grad Sch Med, Tokyo, Japan
[4] RWTH Univ Hosp Aachen, Aachen, Germany
[5] Univ Hlth Network, Mt Sinai Hosp, Toronto, ON, Canada
[6] Univ Hosp Wurzburg, Wurzburg, Germany
[7] Boehringer Ingelheim GmbH & Co KG, Ingelheim, Germany
[8] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA
[9] Boehringer Ingelheim GmbH & Co KG, Hovik, Norway
来源：
EUROPEAN HEART JOURNAL | 2020年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2883 / 2883
页数：1
相关论文
共 50 条
  • [21] Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA-REG OUTCOME trial
    Boehm, Michael
    Slawik, Jonathan
    Brueckmann, Martina
    Mattheus, Michaela
    George, Jyothis T.
    Ofstad, Anne Pernille
    Inzucchi, Silvio E.
    Fitchett, David
    Anker, Stefan D.
    Marx, Nikolaus
    Wanner, Christoph
    Zinman, Bernard
    Verma, Subodh
    EUROPEAN JOURNAL OF HEART FAILURE, 2020, 22 (01) : 126 - 135
  • [22] Empagliflozin in Heart Failure With Predicted Preserved Versus Reduced Ejection Fraction: Data From the EMPA-REG OUTCOME Trial
    Savarese, Gianluigi
    Uijl, Alicia
    Lund, Lars H.
    Anker, Stefan D.
    Asselbergs, Folkert
    Fitchett, David
    Inzucchi, Silvio E.
    Koudstaal, Stefan
    Ofstad, Anne Pernille
    Schrage, Benedikt
    Vedin, Ola
    Wanner, Christoph
    Zannad, Faiez
    Zwiener, Isabella
    Butler, Javed
    JOURNAL OF CARDIAC FAILURE, 2021, 27 (08) : 888 - 895
  • [23] Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)
    Bernard Zinman
    Silvio E Inzucchi
    John M Lachin
    Christoph Wanner
    Roberto Ferrari
    David Fitchett
    Erich Bluhmki
    Stefan Hantel
    Joan Kempthorne-Rawson
    Jennifer Newman
    Odd Erik Johansen
    Hans-Juergen Woerle
    Uli C Broedl
    Cardiovascular Diabetology, 13
  • [24] Consistent effect of empagliflozin on composite outcomes related to heart failure: results from EMPA-REG OUTCOME
    Schnee, J.
    Inzucchi, S. E.
    Zinman, B.
    McGinniss, J.
    George, J. T.
    Fitchett, D.
    DIABETOLOGIA, 2017, 60 : S85 - S86
  • [25] Empagliflozin improves renal outcomes in patients with or without heart failure at baseline - insights from the EMPA-REG OUTCOME trial
    Butler, J. Javed
    Zannad, F.
    Fitchett, D.
    Zinman, B.
    Koitka-Weber, A.
    Von Eynatten, M.
    Hehnke, U.
    George, J.
    Brueckmann, M.
    Cheung, A. K.
    Wanner, C.
    EUROPEAN JOURNAL OF HEART FAILURE, 2018, 20 : 380 - 381
  • [26] Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)
    Zinman, Bernard
    Inzucchi, Silvio E.
    Lachin, John M.
    Wanner, Christoph
    Ferrari, Roberto
    Fitchett, David
    Bluhmki, Erich
    Hantel, Stefan
    Kempthorne-Rawson, Joan
    Newman, Jennifer
    Johansen, Odd Erik
    Woerle, Hans-Juergen
    Broedl, Uli C.
    CARDIOVASCULAR DIABETOLOGY, 2014, 13
  • [27] Improvements in Liver Enzymes with Empagliflozin in the EMPA-REG OUTCOME Trial
    Sattar, Naveed
    Fitchett, David H.
    Hantel, Stefan
    George, Jyothis T.
    Zinman, Bernard
    DIABETES, 2018, 67
  • [28] Effect of empagliflozin on cardiac biomarkers in a zebrafish model of heart failure: clues to the EMPA-REG OUTCOME trial?
    Xingjuan Shi
    Subodh Verma
    Junghwa Yun
    Koroboshka Brand-Arzamendi
    Krishna K. Singh
    Xiangdong Liu
    Ankit Garg
    Adrian Quan
    Xiao-Yan Wen
    Molecular and Cellular Biochemistry, 2017, 433 : 97 - 102
  • [29] CONSISTENT EFFECT OF EMPAGLIFLOZIN ON COMPOSITE OUTCOMES RELATED TO HEART FAILURE: RESULTS FROM EMPA-REG OUTCOME
    Inzucchi, Silvio E.
    Zinman, Bernard
    McGinniss, Jennifer
    Schnee, Janet
    George, Jyothis
    Fitchett, David
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 69 (11) : 1656 - 1656
  • [30] Effect of empagliflozin on cardiac biomarkers in a zebrafish model of heart failure: clues to the EMPA-REG OUTCOME trial?
    Shi, Xingjuan
    Verma, Subodh
    Yun, Junghwa
    Brand-Arzamendi, Koroboshka
    Singh, Krishna K.
    Liu, Xiangdong
    Garg, Ankit
    Quan, Adrian
    Wen, Xiao-Yan
    MOLECULAR AND CELLULAR BIOCHEMISTRY, 2017, 433 (1-2) : 97 - 102
12345